<?xml version="1.0" encoding="UTF-8"?>
<ref id="ddr21709-bib-0066">
 <mixed-citation publication-type="miscellaneous" id="ddr21709-cit-0066">
  <string-name>
   <surname>Gordon</surname>, 
   <given-names>D. E.</given-names>
  </string-name>, 
  <string-name>
   <surname>Jang</surname>, 
   <given-names>G. M.</given-names>
  </string-name>, 
  <string-name>
   <surname>Bouhaddou</surname>, 
   <given-names>M.</given-names>
  </string-name>, 
  <string-name>
   <surname>Xu</surname>, 
   <given-names>J.</given-names>
  </string-name>, 
  <string-name>
   <surname>Obernier</surname>, 
   <given-names>K.</given-names>
  </string-name>, 
  <string-name>
   <surname>O'Meara</surname>, 
   <given-names>M. J.</given-names>
  </string-name>, &amp; 
  <string-name>
   <surname>Krogan</surname>, 
   <given-names>N. J.</given-names>
  </string-name> (
  <year>2020</year>). A SARS‐CoV‐2‐human protein‐protein interaction map reveals drug targets and potential drug‐repurposing. 
  <italic>bioRxiv</italic>, 2020.2003.2022.002386. doi:
  <pub-id pub-id-type="doi">10.1101/2020.03.22.002386%J</pub-id>
 </mixed-citation>
</ref>
